Get in touch (813) 875-6600

Press Releases

January 31, 2017

Morphogenesis Announces Issuance of US Patent for Cancer Vaccines under Expedited Cancer Moonshot Immunotherapy Program

TAMPA, FL – Morphogenesis, Inc., a biotechnology company focused on the development of cell and gene therapies for the treatment of cancer, today announced that the United States Patent and Trademark Office has issued US Patent 9,555,988 covering methods for treating cancer using gene therapy.

Read More patents

October 19, 2016

Biotech innovator Morphogenesis, Inc. launches hi-tech digital stock offering to fight cancer

Morphogenesis, Inc., a biotechnology company headquartered in Tampa, FL, announces its plans to raise up to $20 million from the sale of its common stock to accredited investors. The company is not only embracing new securities industry rules, it is launching what it hopes to be a uniquely efficient capital raising process made possible by the confluence of social and technological changes.

Read More

October 10, 2016

Morphogenesis and Veterinary Oncology Services to showcase multi-indication veterinary immunotherapies at the 2016 Veterinary Cancer Society Conference Morphogenesis, Inc. and its veterinary subsidiary, Veterinary Oncology Services, Inc. (VOS), will be making several presentations at the Veterinary Cancer Society’s (VCS) 36th Annual Conference at the Hilton Lake Buena Vista Resort in Orlando, FL, October 20-22, 2016. VOS will also be hosting a booth to promote its IFx-VET personalized immunotherapy for pets with cancer. Read More vcs-conflogo_20161012

June 27, 2016

Morphogenesis Inc., host to the White House Cancer Moonshot Summit in Tampa Bay, hopes to give voice to thousands through its online event The Vice President of the United States has called together the entire cancer community—researchers, doctors scientists, philanthropists, advocates, patients and survivors for the Cancer Moonshot Summit on June 29, 2016. The goal of the Cancer Moonshot Summit is to double the rate of progress in cancer prevention, diagnosis, treatment and care over the next five years and to ultimately end cancer as we know it. Morphogenesis, Inc. will host one of hundreds of summits around the country in conjunction with the Cancer Moonshot Summit held in Washington, DC. Read More

April 20, 2016

TWO TAMPA INSTITUTIONS JOIN FORCES TO COMBAT ONE OF FLORIDA’S BIGGEST HEALTH CHALLENGES Moffitt Cancer Center and Morphogenesis team up to test new melanoma therapy Morphogenesis, Inc., a research and development company, announced today it is partnering with Moffitt Cancer Center to test an innovative new way to treat one of Florida’s biggest health challenges – melanoma. Florida ranks second, behind California, in the number of new cases of melanoma each year. It was estimated by the American Cancer Society that in 2015, 5,480 new cases of melanoma would be diagnosed in the State. Read More

September 8, 2014

Odyssey Marine Exploration and Morphogenesis discover biotech ‘treasures’ in the deep Researchers at biotech firm Morphogenesis have identified marine microorganisms that will yield critical pharmaceuticals such as anti-cancer drugs and antibiotics from seafloor sediment samples harvested by Odyssey. Read More

September 5, 2014

Morphogenesis announces USDA-sanctioned clinical trial for promising equine cancer vaccine Morphogenesis Inc., the biotechnology firm developing ImmuneFx, a cancer vaccine that has improved the longevity and quality of life for dogs, cats and horses, announces that a formal equine clinical trial for the direct injection form of the vaccine will begin later this month at a large equine facility in Missouri.  Read More

August 26, 2014

Morphogenesis Announces Clinical Trials For Promising Equine Cancer Vaccine Horses indicating melanoma needed as candidates for this major clinical study. Read More

April 5, 2014

Ashraf Dehlawi At Morphogenesis Earns Honors From American Society For Clinical PathologyThe American Society for Clinical Pathology has honored Ashraf Dehlawi, Chief Clinical Officer at Morphogenesis Inc., with inclusion in its prestigious 40-Under-40 honors program. Read More

January 5, 2014

Cancer Researchers at Morphogenesis Complete New Book; “Excellent Volume” Is Most Up-To-Date Look At Cancer Vaccines Drs. Michael J.P. Lawman and Patricia D. Lawman, founders of the Tampa-based biotech firm Morphogenesis Inc., announce the publication of “Cancer Vaccines: Methods and Protocols,” the most definitive work to date in the promising field of cancer vaccines. Read More

December 3, 2013

Promising Canine Cancer Vaccine Tests Begin in Tri-State; Dr. Gerry Post Calls For Volunteer Dogs To Take Part In Study Prominent local veterinarian Dr. Gerry Post, owner of The Veterinary Cancer Center, is calling for owners of dogs with lymphoma in the region to find out if their dogs qualify to take part in clinical trials for a promising new vaccine that has been shown to diminish the effects of multiple types of cancer in dogs, cats and horses. Read More

November 4, 2013

Morphogenesis Inc. CEO Patricia D. Lawman, PhD Named to USF Department of Molecular Medicine Patricia D. Lawman, PhD, CEO of Morphogenesis Inc., has been named an Affiliate Assistant Professor for the Department of Molecular Medicine at the University of South Florida’s Morsani College of Medicine. Read More

May 4, 2010

Morphogenesis, Inc. Announces Issuance of Key Patent allowing the Treatment of Leukemic Conditions using its MG1Antibody Morphogenesis, Inc. announced today that another patent on its MG-1 stem cell marker and monoclonal antibody (7,709,000 B2) has been issued by the United States Patent Office. MG-1, a cell surface marker discovered by scientists at Morphogenesis has demonstrated the ability to identify a small percentage bone marrow stem cells. The Company believes that the MG-1 marker is expressed by the most primitive bone marrow stem cells discovered to date. The issuance of this patent tightens the very strong band of intellectual property protection surrounding this technology and provides the Company exclusive rights to use the MG1 antibody to treat leukemic conditions. Read More

August 19, 2010

Dr. Michael Lawman Receives Third Hyundai Grant For the third year in a row, Dr. Michael Lawman has been awarded a grant from the Hyundai Motor Corporation for his research in children’s cancers. Read More

September, 2009

Morphogenesis Wins PACT Translational Grant Baylor College will perform a key piece of research for Morphogenesis in preparation of its PhI/II Im-muneFx clinical trial with funding from the National Heart Lung and Blood Institute. Read More

July 16, 2009

Morphogenesis a Finalist in the 2009 World Technology Network Award for Biotechnology On July 16, 2009, Morphogenesis, Inc. was named a finalist for the 2009 World Technology Network Award in the biotechnology corporate category. The World Technology Network is a “global meeting ground” whose membership of approximately 1000 members from more than 60 countries reviews hundreds of individual and corporate nominations for this prestigious award. Read More

June 17, 2009

Lawman Lab Recieves Hyundai Grant 2nd Year in a Row For the second year in a row, Dr. Michael Lawman has been awarded a grant from the Hyundai Motor Corporation for his research in children’s cancers. A $35,000 check was delivered as part of the “Hope on Wheels” festivities held at the entrance of the St. Joseph’s Children’s Hospital on June 17, 2009. Read More

December, 2008

Faces of Technology:The Canine Connection The Florida High Tech Corridor Council has featured Morphogenesis as one of 15 Corridor companies in various industries driving innovation and entrepreneurship in an article entitled “Faces of Technology‟. Read More

March 25, 2008

Morphogenesis, Inc. Receives Patent on Immunotherapy for Cancer Morphogenesis, Inc. received a US Patent (7,348,015) today, entitled “Antigen modified cancer cell vaccines for cancer therapy.” This patent is the second in a series of patents expected to be approved by the US patent office has been issued. Read More

June 24, 2007

Morphogenesis, Inc. Announces Issuance of Key Stem Cell Patent Morphogenesis, Inc. announced today that another patent on its MG-1 stem cell marker and monoclonal antibody (7,247,718) has been issued by the United States Patent Office. MG-1 is a cell surface marker discovered by scientists at Morphogenesis which has demonstrated the ability to identify a small percentage bone marrow stem cells. Read More

April 20, 2005

Morphogenesis, Inc. Announces ImmuneFx™ Pre-clinical Results Morphogenesis, Inc. announced today that its cancer therapy, ImmuneFx™, was able to induce tumor regression in mice with an aggressive form of cancer. The news was made public at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, California where basic and clinical researchers gathered to review the latest discoveries in diagnosis, treatment and prevention of cancer. Read More